TY - JOUR T1 - Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine JF - medRxiv DO - 10.1101/2022.02.25.22271494 SP - 2022.02.25.22271494 AU - Tal Patalon AU - Yaki Saciuk AU - Asaf Peretz AU - Galit Perez AU - Yoav Lurie AU - Yasmin Maor AU - Sivan Gazit Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/26/2022.02.25.22271494.abstract N2 - The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2 mRNA Coronavirus Disease 2019 vaccine has yet to be sufficiently researched, while global discussions around the necessity and effectiveness of a fourth dose are already underway. By conducting a retrospective study implementing a test-negative case-control design, analyzing 546,924 PCR tests performed throughout January 2022 by 389,265 persons who received three doses of the vaccine, we found that the effectiveness in each month since vaccination decreased significantly. Compared to those vaccinated early, on August 2021, relative protection against infection waned from 53.4% a month after vaccination to 16.5% three months after vaccination. These results suggest that there is a significant waning of vaccine effectiveness against the Omicron variant of the third dose of the BNT162b2 vaccine within a few months after administration and should prompt policy discussion as to additional booster doses and vaccine development.Competing Interest StatementYM received lecture fees and a quality grant from Pfizer. All other authors declare they have no conflict of interest.Funding StatementThere was no external funding for the project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the MHS (Maccabi Healthcare Services) Institutional Review Board. Due to the retrospective design of the study, informed consent was waived by the IRB, as all identifying details of the participants were removed before computational analysis.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccording to the Israel Ministry of Health regulations, individual-level data cannot be shared openly. Specific requests for remote access to de-identified community-level data should be referred to KSM, Maccabi Healthcare Services Research and Innovation Center. ER -